AGW0 Stoklara Genel Bakış Algernon Pharmaceuticals Inc. Kanada ve Avustralya'da klinik aşamada ilaç geliştirme şirketi olarak faaliyet göstermektedir. Daha fazla detay
Ödüller Risk Analizi + 1 daha fazla risk
Tüm Risk Kontrollerini Gör {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Algernon Pharmaceuticals Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Algernon Pharmaceuticals Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı CA$0.058 52 Haftanın En Yüksek Seviyesi CA$0.093 52 Haftanın En Düşük Seviyesi CA$0.015 Beta -0.25 1 Aylık Değişim -27.95% 3 Aylık Değişim 31.82% 1 Yıllık Değişim -22.67% 3 Yıllık Değişim -94.90% 5 Yıllık Değişim -94.20% Halka arzdan bu yana değişim -99.60%
Son Haberler & Güncellemeler
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO for Repirinast in Kidney Disease Patent Jan 06
Less than half of directors are independent Dec 30 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.2352 million in funding Aug 20
New major risk - Shareholder dilution Aug 15 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Aug 08
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.408 million in funding Aug 02
Daha fazla güncelleme görün
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO for Repirinast in Kidney Disease Patent Jan 06
Less than half of directors are independent Dec 30 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.2352 million in funding Aug 20
New major risk - Shareholder dilution Aug 15 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Aug 08
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.408 million in funding Aug 02
Algernon Pharmaceuticals Inc. Reports Results of Study Showing 93% Cough Suppression with Ifenprodil Jul 16 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.25 million in funding Jul 12
New major risk - Shareholder dilution Jun 10
New major risk - Shareholder dilution May 13
Algernon Pharmaceuticals Inc., Annual General Meeting, Jul 10, 2024 Apr 28 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding Apr 11
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset Apr 03
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis Jan 25 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding Dec 28
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Dec 13
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD Nov 30 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding Jul 15
Algernon Pharmaceuticals Inc. Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase Feb 17
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board Jan 12
Algernon Pharmaceuticals Inc. Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil Jan 10
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis Dec 06
Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study Nov 17
Less than half of directors are independent Nov 16
Algernon Pharmaceuticals Inc. Enters into A Clinical Trial Agreement with Yale University for A DMT Phase 2 Depression Study Nov 09
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. Fda for Ifenprodil as A Treatment of IPF Sep 20
Algernon Pharmaceuticals Inc. Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study Sep 13
Algernon Pharmaceuticals Inc. Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Sep 02 Algernon Pharmaceuticals Inc. announced that it has received funding from AlphaNorth Asset Management Aug 28
Algernon Pharmaceuticals Inc. announced that it has received CAD 1.402125 million in funding Aug 24
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1.402125 million in funding Aug 20
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1.402125 million in funding Aug 19
Algernon Pharmaceuticals Reports Additional Positive Data from Its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Jul 29
Algernon Pharmaceuticals Hits Co-Primary Endpoint in Its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough Jul 19
Algernon Pharmaceuticals Inc. Provides Update on Its Planned Phase 1 Repirinast Chronic Kidney Disease Study Jul 12
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study Jul 08 Algernon Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 1.159189 million. Jul 05
Algernon Pharmaceuticals Inc. Announces Patients Requested Ongoing Supply of Ifenprodil After IPF and Chronic Cough Phase 2 Study Ended Jun 22 Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough Jun 14
Algernon Pharmaceuticals Inc. Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough May 06
Less than half of directors are independent Apr 27
Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study Apr 27
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program Feb 24
Algernon Pharmaceuticals Announces Completion of Enrollment in Its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Feb 05
Algernon Pharmaceuticals Inc., Annual General Meeting, Feb 28, 2022 Jan 30
Algernon Pharmaceuticals Inc., Annual General Meeting, Feb 28, 2022 Jan 29
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of Its Psychedelic Drug Dmt Intellectual Property Jan 25
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study Jan 20
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study Jan 16
Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial Dec 03
Chief Financial Officer Michael S. Sadhra has left the company Dec 02
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study Nov 25
Algernon Pharmaceuticals Inc. Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study Sep 24
Algernon Pharmaceuticals Inc. Plans to File Pre-Investigational New Drug Meeting Request with U.S. Food and Drug Administration for NP-120 (Ifenprodil) Phase 2 Chronic Cough Study Sep 21
Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program Aug 12
Algernon Pharmaceuticals Inc. Targets First Human Study of Its Psychedelic Drug DMT Stroke Program for fourth quarter of 2021 Jun 18
Algernon Pharmaceuticals Inc. Launches Pancreatic Cancer Clinical Research Program with Ifenprodil Jun 04
Algernon Pharmaceuticals Inc. Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke May 28
Algernon Pharmaceuticals Inc. Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke May 18
Algernon Pharmaceuticals Inc. Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study May 13
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study May 12
Algernon Pharmaceuticals Inc. Files End of Phase 2 Meeting Request with U.S. FDA for Its Covid-19 Trial of Ifenprodil Apr 27 Hissedar Getirileri AGW0 DE Pharmaceuticals DE Pazar 7D 93.3% -3.5% 2.3% 1Y -22.7% -14.6% 16.7%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: AGW0 geçen yıl % -14.6 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: AGW0 geçen yıl % 16.7 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is AGW0's price volatile compared to industry and market? AGW0 volatility AGW0 Average Weekly Movement 106.2% Pharmaceuticals Industry Average Movement 5.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
İstikrarlı Hisse Senedi Fiyatı: AGW0 hisse senedi fiyatı, son 3 ayda German piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: AGW0 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 75% dan 106% a yükseldi.
Şirket Hakkında Algernon Pharmaceuticals Inc. Kanada ve Avustralya'da klinik aşamada ilaç geliştirme şirketi olarak faaliyet göstermektedir. Şirket, alkolik olmayan steatohepatit, karaciğer hastalığı, kronik böbrek hastalığı ve inme programı alanlarında terapötik ilaçlar geliştirmeye odaklanmaktadır. Boru hattında, idiyopatik pulmoner fibrozis ve kronik öksürük tedavisi için Faz 2b klinik çalışmasında olan Ifenprodil; kronik böbrek hastalığı tedavisi için Faz 1 klinik çalışmasında olan repirinast ve inme ve travmatik beyin yaralanmalarının tedavisi için Faz 1 klinik çalışmasında olan N,N-Dimetiltriptamin bulunmaktadır.
Daha fazla göster Algernon Pharmaceuticals Inc. Temel Bilgiler Özeti Algernon Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? AGW0 temel i̇stati̇sti̇kler Piyasa değeri €2.21m Kazançlar(TTM ) -€244.72k Gelir(TTM ) n/a
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) AGW0 gelir tablosu (TTM ) Gelir CA$0 Gelir Maliyeti CA$0 Brüt Kâr CA$0 Diğer Giderler CA$362.49k Kazançlar -CA$362.49k
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/02/11 06:41 Gün Sonu Hisse Fiyatı 2025/02/11 00:00 Kazançlar 2024/11/30 Yıllık Kazançlar 2024/08/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Algernon Pharmaceuticals Inc. 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Andre Uddin Research Capital Corporation
